Jamaica’s head of the Cannabis Licensing Authority (CLA) is hopefully after the FDA approved the pot-derived medicine called Epidiolex.
CLA’s head Lincoln Allen said Thursday that the recent approval of Epidiolex, a CBD-based medicine by the US federal agency, the FDA, for the treatment of epilepsy could pave the way for transformation in the global medicinal cannabis space.
Allen also said there was room for development in the research and innovation of marijuana.
Allen made the statement at the University of Technology’s (UTech) Jamaican Medical Cannabis Integration Symposium (JAMECANN) opening ceremony titled: ‘Merging Science, Spirit, and Business.’
He said CLA is understanding of the role that academia plays in promoting the development of innovation.
Cannabis part of Jamaica
He went on to explain that cannabis medicinal benefits are part of Jamaica’s home remedies, and the push in developmental research is key in producing results in health and wellbeing.
“It is through research, often pioneered by academia, and through the hosting of symposia and the inclusion of various working groups such as these (JAMECANN) that has helped to broaden the scope of understanding, learning, knowledge transfer as well as innovation, which this industry currently needs in order to be viable and sustainable.”